Impact of the Inflation Reduction Act on the 340B Program

The 340b program provides an important revenue source for many HIV clinics and facilities, but that revenue is dependent on drug pricing. The Inflation Reduction Act of 2022 introduced provisions to curb drug pricing. Our modeling suggests that 340b revenues generated from HIV-related prescriptions could decrease by as much as 50% if drug prices are lowered by manufacturers in response to the Act.